← Leaderboards
Bosco Bwana
Massachusetts General Hospital
$1,231,466
Attributed
$2,462,932
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $656.1K · FY2016–19$1M$750K$500K$250K$0
'16
'17
'18
'19
Funding mix
By agency
NIH$2,462,932 · 1
By mechanism
R01$2,462,932 · 1
Top collaborators
- Mark J Siedner4 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Elyse R Park$12,238,672
- Benjamin P Linas$16,281,715
- Zhongcong Xie$19,705,169
- Patrick Thomas Ellinor$17,149,392
- Steven A Safren$27,216,676
Others in their field
Top investigators on “Ensure”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Jeffrey P Krischer · University Of South Florida$385,823,280
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
- Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$315,257,203
Research focus
EnsureEnrollmentAchievementAids PreventionAfrica South Of The SaharaBaseAdherenceCaringClinicClinical ManagementAntiretroviral TherapyCostCost EffectiveCost EffectivenessAids/Hiv ProblemCost SavingsCountryDetectionDiagnosticDrug ResistanceEffectivenessEmergency SituationContinuity Of Patient CareEpidemic
Grant awards (4)
Resistance testing versus adherence support for management of patients with virologic failure on first-line antiretroviral therapy in sub-Saharan Africa: An open-label randomized controlled trial$656,150
R01 · FY2019 · AI
Resistance testing versus adherence support for management of patients with virologic failure on first-line antiretroviral therapy in sub-Saharan Africa: An open-label randomized controlled trial$565,060
R01 · FY2018 · AI
Resistance testing versus adherence support for management of patients with virologic failure on first-line antiretroviral therapy in sub-Saharan Africa: An open-label randomized controlled trial$588,913
R01 · FY2017 · AI
Resistance testing versus adherence support for management of patients with virologic failure on first-line antiretroviral therapy in sub-Saharan Africa: An open-label randomized controlled trial$652,809
R01 · FY2016 · AI